Tocilizumab in severe to critically ill COVID-19 patients: does timing matter?

Abstract

Purpose
Tocilizumab reduces inflammation during cytokine storms, a key driver of acute respiratory distress syndrome (ARDS) in COVID-19. This study evaluates the impact of tocilizumab timing on outcomes in severe to critically ill COVID-19 patients.


Methods
This prospective study included patients with severe to critical COVID-19 pneumonia. Patients were divided into two groups: Group 1 received tocilizumab within 10 days of symptom onset along with standard care, while Group 2 received it after 10 days.


Results
No significant differences were observed between the early and late administration groups in mortality (18.6% vs. 18.4%), need for noninvasive ventilation (32.2% vs. 28.6%), invasive mechanical ventilation (20.6% vs. 20.4%), secondary bacterial infection (20.6% vs. 26.5%), mean days of oxygen support (11.03 vs. 10.57), ICU stay (9.19 vs. 9.36 days), or hospital stay (12.66 vs. 12.98 days).
However, patients who received tocilizumab within 48 h had a shorter duration of oxygen support (10.25 vs. 12.49 days) and hospital stay (12.25 vs. 14.68 days) (p = 0.021 and 0.005, respectively).


Conclusion
In patients with severe COVID-19 pneumonia, administering tocilizumab within the first 10 days of symptom onset did not significantly impact mortality, duration of oxygen support, or length of hospital stay. However, earlier administration (within 48 h) was associated with a shorter duration of oxygen support and reduced hospital stay.